Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study

被引：4

作者：

Okada, Takuro ^{[1
,7
]}

Fushimi, Chihiro ^{[2
]}

Matsuki, Takashi ^{[3
]}

Tokashiki, Kunihiko ^{[1
]}

Takahashi, Hideaki ^{[4
]}

Okamoto, Isaku ^{[1
]}

Sato, Hiroki ^{[1
]}

Kondo, Takahito ^{[5
]}

Hanyu, Kenji ^{[1
]}

Kishida, Takuma ^{[1
]}

Ito, Tatsuya ^{[1
]}

Yamashita, Gai ^{[1
]}

Masubuchi, Tatsuo ^{[2
]}

Tada, Yuichiro ^{[2
]}

Miura, Koki ^{[2
]}

Omura, Go ^{[6
]}

Yamashita, Taku ^{[3
]}

Oridate, Nobuhiko ^{[4
]}

Tsukahara, Kiyoaki ^{[1
]}

机构：

[1] Tokyo Med Univ, Dept Otorhinolaryngol Head & Neck Surg, Tokyo, Japan

[2] Int Univ Hlth, Welf Mita Hosp, Dept Head & Neck Oncol & Surg, Tokyo, Japan

[3] Kitasato Univ, Dept Otorhinolaryngol Head & Neck Surg, Sch Med, Sagamihara, Japan

[4] Yokohama City Univ, Dept Otorhinolaryngol, Head & Neck Surg, Yokohama, Japan

[5] Tokyo Med Univ, Dept Otorhinolaryngol Head & Neck Surg, Hachioji Med Ctr, Tokyo, Japan

[6] Natl Canc Ctr, Dept Head & Neck Oncol, Tokyo, Japan

[7] Tokyo Med Univ, Dept Otorhinolaryngol Head & Neck Surg, 6-7-1 Nishishinjuku,Shinjuku ku, Tokyo 1600023, Japan

来源：

ANTICANCER RESEARCH | 2023年 / 43卷 / 06期

关键词：

Key Words; Squamous cell carcinoma; head and neck; pembrolizumab; immune checkpoint inhibitor; IMMUNE CHECKPOINT INHIBITORS; SALVAGE CHEMOTHERAPY; METASTATIC HEAD; RESPONSE RATES; RECURRENT; NIVOLUMAB; EFFICACY;

D O I：

10.21873/anticanres.16438

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Pembrolizumab exhibits anticancer efficacy in platinum-sensitive or platinum-unfit patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, no large-scale retrospective real-world data are available. This retrospective study aimed to examine the efficacy and safety of pembrolizumab in multiple facilities. Patients and Methods: Data of 167 patients with R/M SCCHN treated with pembrolizumab between December 2019 and February 2022 were analyzed. The endpoint was overall survival (OS), progression-free survival (PFS), and immune-related adverse events (irAEs). OS and PFS were analyzed comparatively with and without irAEs, and complete response (CR) or partial response (PR), and stable disease (SD) or progressive disease received pembrolizumab alone, whereas the others received pembrolizumab with chemotherapy. For the pembrolizumab only g oup, the median OS and PFS were 22.7 and 5.1 months,respectively. There were significant differences in OS and PFS between CR or PR and SD or PD (p<0.01, p<0.01, respectively). For pembrolizumab with chemotherapy, the OS was not reached and median PFS was 7.0 months. There was a significant difference in PFS between CR or PR and SD or PD (p<0.01). There was a significant difference in PFS between patients with and without irAEs (p=0.02). Conclusion: The real-world therapeutic effect of pembrolizumab for R/M SCCHN was comparable to that observed in the KEYNOTE048 trial. In addition, irAEs and best overall response were considered as prognostic factors.

引用

页码：2717 / 2724

页数：8

共 21 条

[1]

[Anonymous], COMMON TERMINOLOGY C

[2] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].

Burtness, Barbara ;

Harrington, Kevin J. ;

Greil, Richard ;

Soulieres, Denis ;

Tahara, Makoto ;

de Castro, Gilberto, Jr. ;

Psyrri, Amanda ;

Baste, Neus ;

Neupane, Prakash ;

Bratland, Ase ;

Fuereder, Thorsten ;

Hughes, Brett G. M. ;

Mesia, Ricard ;

Ngamphaiboon, Nuttapong ;

Rordorf, Tamara ;

Ishak, Wan Zamaniah Wan ;

Hong, Ruey-Long ;

Mendoza, Rene Gonzalez ;

Roy, Ananya ;

Zhang, Yayan ;

Gumuscu, Burak ;

Cheng, Jonathan D. ;

Jin, Fan ;

Rischin, Danny .

LANCET, 2019, 394 (10212) :1915-1928

[3] Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial [J].

Eggermont, Alexander M. M. ;

Kicinski, Michal ;

Blank, Christian U. ;

Mandala, Mario ;

Long, Georgina V. ;

Atkinson, Victoria ;

Dalle, Stephane ;

Haydon, Andrew ;

Khattak, Adnan ;

Carlino, Matteo S. ;

Sandhu, Shahneen ;

Larkin, James ;

Puig, Susana ;

Ascierto, Paolo A. ;

Rutkowski, Piotr ;

Schadendorf, Dirk ;

Koornstra, Rutger ;

Hernandez-Aya, Leonel ;

Di Giacomo, Anna Maria ;

van den Eertwegh, Alfonsus J. M. ;

Grob, Jean-Jacques ;

Gutzmer, Ralf ;

Jamal, Rahima ;

Lorigan, Paul C. ;

Krepler, Clemens ;

Ibrahim, Nageatte ;

Marreaud, Sandrine ;

van Akkooi, Alexander ;

Robert, Caroline ;

Suciu, Stefan .

JAMA ONCOLOGY, 2020, 6 (04) :519-527

[4] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[5] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].

Ferris, R. L. ;

Blumenschein, G., Jr. ;

Fayette, J. ;

Guigay, J. ;

Colevas, A. D. ;

Licitra, L. ;

Harrington, K. ;

Kasper, S. ;

Vokes, E. E. ;

Even, C. ;

Worden, F. ;

Saba, N. F. ;

Iglesias Docampo, L. C. ;

Haddad, R. ;

Rordorf, T. ;

Kiyota, N. ;

Tahara, M. ;

Monga, M. ;

Lynch, M. ;

Geese, W. J. ;

Kopit, J. ;

Shaw, J. W. ;

Gillison, M. L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867

[6] Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma [J].

Fushimi, Chihiro ;

Okamoto, Isaku ;

Matsuki, Takashi ;

Masubuchi, Tatsuo ;

Okada, Takuro ;

Sato, Hiroki ;

Tsukahara, Kiyoaki ;

Kondo, Takahito ;

Yamashita, Taku ;

Hanyu, Kenji ;

Omura, Go ;

Takahashi, Hideaki ;

Tada, Yuichiro ;

Miura, Kouki .

ANTICANCER RESEARCH, 2020, 40 (09) :5277-5283

[7] Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma [J].

Guiard, Emeline ;

Clatot, Florian ;

Even, Caroline ;

Perreard, Marion ;

Abdeddaim, Cyril ;

Johnson, Alison ;

Vauleon, Elodie ;

Rambeau, Audrey .

EUROPEAN JOURNAL OF CANCER, 2021, 159 :125-132

[8] Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer [J].

Haratani, Koji ;

Hayashi, Hidetoshi ;

Chiba, Yasutaka ;

Kudo, Keita ;

Yonesaka, Kimio ;

Kato, Ryoji ;

Kaneda, Hiroyasu ;

Hasegawa, Yoshikazu ;

Tanaka, Kaoru ;

Takeda, Masayuki ;

Nakagawa, Kazuhiko .

JAMA ONCOLOGY, 2018, 4 (03) :374-378

[9] PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer [J].

Ito, Tatsuya ;

Okamoto, Isaku ;

Tokashiki, Kunihiko ;

Sato, Hiroki ;

Okada, Takuro ;

Yamashita, Gai ;

Nagao, Toshitaka ;

Hirai, Hideaki ;

Saigusa, Natsuki ;

Tsukahara, Kiyoaki .

ANTICANCER RESEARCH, 2022, 42 (03) :1547-1554

[10] Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].

Kanda, Y. .

BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458

← 1 2 3 →